Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shanghai Kechow Pharma Inc. operates a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action. This activity is assigned to 1 distinct examiner and 1 distinct art unit, showing a very specific and centralized prosecution focus for the company's active patent applications. This arrangement suggests that the company is currently focusing its intellectual property efforts on a 1 pharmaceutical innovation.
MOORE, SUSANNA is the busiest examiner for this portfolio, holding 1 busiest examiner pending office action. This single action represents the total 1 pending office action for the company. With 1 distinct examiner and 1 distinct art unit, the company's current engagement with the patent office is limited to a 1 point of review. This concentration means that the company's immediate patenting outcomes are entirely subject to the examination style and technical interpretations of this 1 individual within the biotechnology field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOORE, SUSANNA | 1 | 68.0% | +31.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17618870 | USE OF AMINOTHIOL COMPOUNDS AS CEREBRAL NERVE OR HEART PROTECTIVE AGENT | MOORE, SUSANNA | 55d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17618870 | USE OF AMINOTHIOL COMPOUNDS AS CEREBRAL NERVE OR HEART PROTECTIVE AGENT | MOORE, SUSANNA | 55d |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17618870 | USE OF AMINOTHIOL COMPOUNDS AS CEREBRAL NERVE OR HEART PROTECTIVE AGENT | MOORE, SUSANNA | 1624 | §103§112 | Final Rejection | 55d | Pending | Dec 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Kechow Pharma Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Susanna Moore has the most, with 1 of Shanghai Kechow Pharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
